To evaluate the effects of 17-aminogeldanamycin on the p65/NF-κB program in melanoma, we used six patient-derived cell lines, representing different genetic subtypes, either BRAFV600E (DMBC11, DMBC12, DMBC21, DMBC28, and DMBC29) or NRASQ61R (DMBC22) subtypes. The gene discussed is NFKB1; the disease is melanoma.